Preterm Birth Prevention and Management Market Size

Preterm Birth Prevention and Management Market Outlook from 2024 to 2034

The global preterm birth prevention and management market size is estimated to stand at US$ 1.70 billion in 2024. As both developed and developing countries embrace therapeutics for preventing and managing preterm birth, the market is expected to exceed a valuation of US$ 4.49 billion by 2034, registering an impressive CAGR of 10.2%.

Preterm Birth Prevention and Management Market Overview:

Preterm birth prevention and management demand is on the rise since preterm birth has become a key healthcare problem. It is making a significant impact on both disability and perinatal death.
By 2034, there is likely to be a 2.65X surge in the adoption of preterm birth prevention and management. Healthcare professionals are implementing diverse strategies for preventing preterm birth
. This is propelling advancements in the market, with a foreseeable continuation of this trend.
The global trends in the preterm birth prevention and management industry spotlight a shift toward personalized and patient-centric care.

Attributes	Details
Preterm Birth Prevention and Management Market Size (2024)	US$ 1.70 billion
Preterm Birth Prevention and Management Market Forecasted Size (2034)	US$ 4.49 billion
Projected Value CAGR (2024 to 2034)	10.2%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Key Factors Influencing the Preterm Birth Prevention and Management Market Growth

Global Concerns Soar as Premature Births Skyrocket! One of the main concerns for governments and medical professionals globally nowadays is the startling rise in the frequency of premature births.

Government and nonprofit organizations have periodically implemented multiple measures to provide an adequate infrastructure for prenatal care. To decrease the number of recurring preterm birth cases, the National Consumer League (NCL) and patient advocacy organizations established the Preterm Birth Prevention Alliance (PBPA) in 2021.
The market is growing as a result of a rise in the use of preterm diagnostic tests for improved evaluation. Apart from the obvious risks that preterm birth poses to both the mother's and baby's lives, it also results in significant monetary consequences.

Maternal and Neonatal Health in the Spotlight! The increasing demand is rooted in the recognition of its profound impact on neonatal care in preterm births.

The World Health Organization (WHO) estimates that 15 million infants are born prematurely each year. This translates to about 11% global rate of premature births.
The rising awareness of the dangers and consequences associated with preterm labor management has led to an increased focus on proactive steps to prevent them.

Health Awareness Surge Fuels Market Boom! The market is also booming due to the expanding health awareness among individuals for preterm labor mitigation.

As information becomes more widely available, pregnant parents are becoming more knowledgeable of the possible dangers and difficulties related to preterm deliveries.
The shift in mindset contributes to the overall prevention and effective fatal health management. The Centers for Disease Control and Prevention report that after rising by 4% between 2020 and 2021, the preterm birth rate decreased by 1% in 2022 to 10.4%.

Targeted Therapies Take Center Stage in Preterm Birth Prevention! Increasing emphasis on targeted therapies also escalates the adoption rate of preterm birth prevention and management.

Advancements in medical research and technology allow for the development of targeted therapies that specifically address the factors contributing to preterm births.
Preterm births can be strongly prevented and managed with the use of precise medicines like tocolytics and corticosteroids, as well as surgical techniques like cervical cerclage and hydroxyprogesterone caproate.

Historical Preterm Birth Prevention and Management Market Statistic Analysis alongside Future Projections

From 2019 to 2023, the global preterm birth prevention and management industry showed promising growth, boasting a 9.0% CAGR. The application of progesterone and corticosteroid medications, among other therapeutic options, was prompted during this period by growing concerns over the mortality rate and long-term impairment associated with obstetric solutions for preterm delivery. These therapeutic methods are likely to continue to gain favor among individuals. The market for preterm birth prevention and management is anticipated to develop considerably as a result through 2034.

Historical CAGR (2019 to 2023)	9.0%
Forecasted CAGR (2024 to 2034)	10.2%

Prominent companies are actively investing in research to create innovative treatments. They are investigating novel combinations of therapies to successfully treat preterm delivery and associated consequences. By treating the fetus as the patient, University of Texas Medical Branch (UTMB) researchers unveiled a novel therapeutic approach in 2021 with the goal of lowering the prevalence of preterm births.

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Preterm Birth Prevention and Management Market Trends

The evolving trends in the preterm birth prevention and management market indicate a promising shift toward more personalized and innovative approaches. Healthcare professionals and researchers are taking up a holistic perspective after recognizing the multifaceted nature of preterm birth. Modern diagnostics and customized treatment regimens together represent an important shift from the old one-size-fits-all approach.
Encouraging policies and programs from the government are fostering the development of solutions for managing and preventing preterm births.
There has been a noticeable increase in public and healthcare professional awareness initiatives aimed at educating people about the dangers of preterm birth and available early birth prevention strategies.

Preterm Birth Prevention and Management Market Analysis by Region

North America stands out as a dominant force in the preterm birth prevention and management industry. The region boasts a robust healthcare infrastructure, advanced medical research facilities, and a proactive approach towards maternal and infant health. There is likely to be significant growth in Asia Pacific. The increasing awareness of maternal and child healthcare, coupled with advancements in medical technology, creates a promising situation for growth of preterm birth prevention and management.

Country	Forecasted CAGR (2024 to 2034)
United States	8.1%
India	12.8%
China	11.5%
Japan	12.1%
Indonesia	13.0%

Government Initiatives Fuel Preterm Birth Prevention Market in the United States

Demand for preterm birth prevention and management in the United States is set to rise with an anticipated CAGR of 8.1% through 2034. Key factors influencing the demand include:

The government has occasionally implemented a number of programs to create an adequate infrastructure for prenatal care. Leading market players now have a ton of room because of this. The United States Department of Health and Human Services (HHS) provided almost US$ 350 million in grants to states nationwide in September 2021 to promote safe pregnancies and healthy infants. This simultaneously fuels the United States of America digital pregnancy test kits market.
In addition to the government, non-profit groups are concentrating on addressing the issue of premature births, which is propelling market expansion. The Office of Women's Health at Wayne State University, which acts as the SOS MATERNITY Network's coordination hub in Michigan, initiated a preterm birth awareness campaign in November 2023.

India's Preterm Birth Management Market Soars as Programs Multiply

The India preterm birth prevention and management market is forecasted to inflate at a CAGR of 12.8% through 2034. The primary factors bolstering the market expansion are:

In India, there is a growing demand for preterm birth prevention and treatment therapies due to the country's high infant death rate and rising preterm birth incidences. With over 3,519 100 instances, the country continues to be the top contributor to the global burden of preterm births, as reported by the WHO.
To address the growing number of premature babies, both public and private groups are launching multiple programs and campaigns. The government has started the India Newborn Action Plan, which is also known as Karyakram, Rashtriya Bal Suraksha. It establishes special newborn care units and improved labor rooms across the country.

Free Preconception Care Spurs Market Growth in China

Sales of preterm birth prevention and management drugs in China are estimated to record a CAGR of 11.5% through 2034. The main factors supporting this occurrence are:

Preterm birth rates have increased dramatically in China during the past few years. With around 1,172,300 cases, the country is now the second top contributor to the global preterm birth rate, according to the WHO. The preterm birth prevention and management market has gained attention as a result of the increase in preterm birth cases.
Supportive laws and rising government spending on building national infant care facilities are beneficial to market expansion, and this trend is likely to persist. In an effort to lower the frequency of birth abnormalities, the government has started providing free preconception care.

Free Clinic Admission Boosts Japan's Preterm Birth Prevention Market Growth

The preterm birth prevention and management market in Japan is likely to exhibit a CAGR of 12.1% through 2034. Reasons supporting this rapid adoption include:

Even with the strain of rising premature births, preterm birth rates in Japan decreased dramatically when obstetrical guidelines were implemented in 2008. But following 2021, it once more began to rise at an alarming pace.
Over the past three decades, Japan has tried intensive therapy for extremely preterm newborns born at fewer than twenty-five weeks gestation. Pregnant women in Japan are entitled to free clinic admission under the country's medical system.

Government Initiatives Propel Growth in Indonesia's Preterm Birth Management Market

The Indonesia preterm birth prevention and management market is expected to surge at a CAGR of 13.0% through 2034. Top factors supporting the market expansion include:

Preterm birth rates are high in Indonesia, with around 600,000 preterm births reported there each year. The Indonesian healthcare system is heavily burdened by it. As a result, demand for interventions to reduce premature birth risks is growing in Indonesia.
The MCH handbook for small babies and the national guideline for the management of LBW in primary health care, which were recently published by the Indonesian government, present potential for market participants in the area of LBW and premature birth interventions.

Preterm Birth Prevention and Management Market Analysis by Segment

As far as the therapy type is concerned, the progesterone segment is likely to dominate the industry in 2024, accounting for a 61.5% market share. Similarly, the parenteral segment is expected to take the lead when considering the route of administration, commanding a 78.8% preterm birth prevention and management market share in the same year. Likewise, when it comes to the distribution channel, the hospital pharmacies segment is anticipated to lead the way, holding an impressive 56.2% market share for the same year.

Segment	Market Share in 2024
Progesterone Therapy	61.5%
Parenteral	78.8%
Hospital Pharmacies	56.2%

Progesterone Therapy Leads in Preventing Preterm Birth

Progesterone therapy is the top choice for preventing preterm births. The following factors support this choice:

The demand for progesterone therapy is expected to grow rapidly, driven by the increasing adoption of this treatment for preterm birth prevention and management.
It is capable of providing quick results and it is also highly effective, all of which increase its attractiveness in the market.
Healthcare professionals highly recommend progesterone therapy because it doesn't involve surgery or anesthesia.
Progesterone is beneficial in preventing preterm births in cases of a short cervix, previous spontaneous preterm births, and various other pregnancy complications.

Healthcare Workers Prefer Parenteral Administration for Preterm Birth Management

The parenteral route dominates the global preterm birth prevention and management market.

Healthcare workers commonly use parenteral administration for therapeutics like progesterone and corticosteroids.
The parenteral route ensures better bioavailability and reliable dosing and avoids first-pass metabolism.
By bypassing the digestive system, the parenteral route minimizes variability in drug absorption, enhancing therapeutic effectiveness.
Advantages of parenteral administration contribute to its continued prevalence in healthcare practice.

Hospital Pharmacies Lead in Preterm Birth Prevention Medication Distribution

Hospital pharmacies hold the maximum revenue share in the distribution channel for preterm birth prevention and management.

Many patients choose government hospitals for cost-effectiveness, driving demand for preterm birth therapeutics at hospital pharmacies.
Hospital pharmacies, integrated into healthcare institutions, collaborate with various medical departments to provide a comprehensive approach to preterm birth prevention.
Shareholders are consistently investing in hospital pharmacies for the distribution of drugs related to preterm birth prevention and management.

Competitive Landscape

Top companies in the global preterm birth prevention and management market are strategically expanding their global footprint through initiatives like mergers, partnerships, product launches, approvals, collaborations, and acquisitions. These diverse approaches reflect their commitment to addressing preterm birth challenges while positioning themselves as industry leaders. Such dynamic strategies underscore their dedication to advancing healthcare solutions and fostering a broader impact on a global scale.

Recent Developments

The United States Food and Drug Administration authorized Opill®, Perrigo Company plc. announced in July 2023. This over-the-counter (OTC) oral contraceptive is exclusively available for use by adults and is progestin-only. The first birth control pill to be sold over-the-counter in the US was called Opill®.
The United States Food and Drug Administration authorized the Abrysvo (Respiratory Syncytial Virus Vaccine) in August 2023. This is the first vaccination licensed for expectant mothers to prevent severe lower respiratory tract illness (LRTD) and LRTD in babies under six months of age that is caused by the respiratory syncytial virus (RSV).

Key Preterm Birth Prevention and Management Market Players

Aquatic Remedies Pvt. Ltd.
Teva Pharmaceuticals USA, Inc.
Anglo French Drugs & Industries Limited
Biophar Lifesciences Pvt. Ltd.
Jasco Labs (P) Ltd.
BSA Pharma Inc.
Pfizer Inc.
Novartis AG
Sanofi S.A
AMAG Pharmaceuticals
Mylan

Key Segments in the Preterm Birth Prevention and Management Market Report

By Therapy Type:

Progesterone Therapy
Corticosteroid Therapy
Tocolytics Therapy
Antihypertensive Therapy
Magnesium Sulfate Therapy
Heparin Prophylaxis Therapy
Low-Dose Aspirin Therapy
Antibiotics Therapy

By Route of Administration:

Oral
Parenteral
Vaginal

By Patient Type:

Prior Spontaneous PTB
Preeclampsia
Short Cervix
Chronic Hypertension
Insulin-dependent
Twins
Antiphospholipid Antibody Syndrome
Others

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Drug Stores
Mail Order Pharmacies

By Region:

North America
Europe
Latin America
South Asia
East Asia
Oceania
Middle East and Africa

Frequently Asked Questions

How Big is the Preterm Birth Prevention and Management Market?

The preterm birth prevention and management industry is forecasted to be valued at US$ 1.70 billion in 2024.

What is the Demand Forecast of the Preterm Birth Prevention and Management?

The preterm birth prevention and management market Value is projected to surpass US$ 4.49 billion by 2034.

What is the Projected CAGR for the Preterm Birth Prevention and Management Market?

The CAGR of the preterm birth prevention and management industry is estimated to be around 10.2% through 2034.

Which Countries Drive the Demand for Preterm Birth Prevention and Management?

The United States, India, and Indonesia are key consumers of Preterm Birth Prevention and Management.

What is the Prevalence of Preterm Birth in India?

In India, the escalating issue of preterm birth is becoming a significant concern, and there is a projected 12.8% CAGR in the efforts toward its prevention and management.

What are the Global Trends of Preterm Birth?

Global trends in preterm birth show a concerning rise, with inadequate healthcare access and lifestyle changes contributing to an increase in premature deliveries

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

3.2.1. Demand in Optimistic Scenario

3.2.2. Demand in Likely Scenario

3.2.3. Demand in Conservative Scenario

3.3. Opportunity Map Analysis

3.4. Investment Feasibility Matrix

3.5. PESTLE and Porter’s Analysis

3.6. Regulatory Landscape

3.6.1. By Key Regions

3.6.2. By Key Countries

3.7. Regional Parent Market Outlook

4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034

4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023

4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034

4.2.1. Y-o-Y Growth Trend Analysis

4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Therapy Type

5.1. Introduction / Key Findings

5.2. Historical Market Size Value (US$ Million) Analysis By Therapy Type, 2019 to 2023

5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy Type, 2024 to 2034

5.3.1. Progesterone Therapy

5.3.2. Corticosteroid Therapy

5.3.3. Tocolytics Therapy

5.3.4. Antihypertensive Therapy

5.3.5. Magnesium Sulfate Therapy

5.3.6. Heparin Prophylaxis Therapy

5.3.7. Low-Dose Aspirin Therapy

5.3.8. Antibiotics Therapy

5.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2019 to 2023

5.5. Absolute $ Opportunity Analysis By Therapy Type, 2024 to 2034

6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration

6.1. Introduction / Key Findings

6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2019 to 2023

6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2024 to 2034

6.3.1. Oral

6.3.2. Parenteral

6.3.3. Vaginal

6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2019 to 2023

6.5. Absolute $ Opportunity Analysis By Route of Administration, 2024 to 2034

7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Patient Type

7.1. Introduction / Key Findings

7.2. Historical Market Size Value (US$ Million) Analysis By Patient Type , 2019 to 2023

7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Patient Type , 2024 to 2034

7.3.1. Prior Spontaneous PTB

7.3.2. Preeclampsia

7.3.3. Short Cervix

7.3.4. Chronic Hypertension

7.3.5. Insulin-dependent

7.3.6. Twins

7.3.7. Antiphospholipid Antibody Syndrome

7.3.8. Others

7.4. Y-o-Y Growth Trend Analysis By Patient Type , 2019 to 2023

7.5. Absolute $ Opportunity Analysis By Patient Type , 2024 to 2034

8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel

8.1. Introduction / Key Findings

8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2019 to 2023

8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2024 to 2034

8.3.1. Hospital Pharmacies

8.3.2. Retail Pharmacies

8.3.3. Drug Stores

8.3.4. Mail Order Pharmacies

8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023

8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034

9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region

9.1. Introduction

9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023

9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034

9.3.1. North America

9.3.2. Latin America

9.3.3. Western Europe

9.3.4. Eastern Europe

9.3.5. South Asia and Pacific

9.3.6. East Asia

9.3.7. Middle East and Africa

9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

10.2.1. By Country

10.2.1.1. U.S.

10.2.1.2. Canada

10.2.2. By Therapy Type

10.2.3. By Route of Administration

10.2.4. By Patient Type

10.2.5. By Distribution Channel

10.3. Market Attractiveness Analysis

10.3.1. By Country

10.3.2. By Therapy Type

10.3.3. By Route of Administration

10.3.4. By Patient Type

10.3.5. By Distribution Channel

10.4. Key Takeaways

11. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

11.2.1. By Country

11.2.1.1. Brazil

11.2.1.2. Mexico

11.2.1.3. Rest of Latin America

11.2.2. By Therapy Type

11.2.3. By Route of Administration

11.2.4. By Patient Type

11.2.5. By Distribution Channel

11.3. Market Attractiveness Analysis

11.3.1. By Country

11.3.2. By Therapy Type

11.3.3. By Route of Administration

11.3.4. By Patient Type

11.3.5. By Distribution Channel

11.4. Key Takeaways

12. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

12.2.1. By Country

12.2.1.1. Germany

12.2.1.2. U.K.

12.2.1.3. France

12.2.1.4. Spain

12.2.1.5. Italy

12.2.1.6. Rest of Western Europe

12.2.2. By Therapy Type

12.2.3. By Route of Administration

12.2.4. By Patient Type

12.2.5. By Distribution Channel

12.3. Market Attractiveness Analysis

12.3.1. By Country

12.3.2. By Therapy Type

12.3.3. By Route of Administration

12.3.4. By Patient Type

12.3.5. By Distribution Channel

12.4. Key Takeaways

13. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

13.2.1. By Country

13.2.1.1. Poland

13.2.1.2. Russia

13.2.1.3. Czech Republic

13.2.1.4. Romania

13.2.1.5. Rest of Eastern Europe

13.2.2. By Therapy Type

13.2.3. By Route of Administration

13.2.4. By Patient Type

13.2.5. By Distribution Channel

13.3. Market Attractiveness Analysis

13.3.1. By Country

13.3.2. By Therapy Type

13.3.3. By Route of Administration

13.3.4. By Patient Type

13.3.5. By Distribution Channel

13.4. Key Takeaways

14. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

14.2.1. By Country

14.2.1.1. India

14.2.1.2. Bangladesh

14.2.1.3. Australia

14.2.1.4. New Zealand

14.2.1.5. Rest of South Asia and Pacific

14.2.2. By Therapy Type

14.2.3. By Route of Administration

14.2.4. By Patient Type

14.2.5. By Distribution Channel

14.3. Market Attractiveness Analysis

14.3.1. By Country

14.3.2. By Therapy Type

14.3.3. By Route of Administration

14.3.4. By Patient Type

14.3.5. By Distribution Channel

14.4. Key Takeaways

15. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

15.2.1. By Country

15.2.1.1. China

15.2.1.2. Japan

15.2.1.3. South Korea

15.2.2. By Therapy Type

15.2.3. By Route of Administration

15.2.4. By Patient Type

15.2.5. By Distribution Channel

15.3. Market Attractiveness Analysis

15.3.1. By Country

15.3.2. By Therapy Type

15.3.3. By Route of Administration

15.3.4. By Patient Type

15.3.5. By Distribution Channel

15.4. Key Takeaways

16. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023

16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034

16.2.1. By Country

16.2.1.1. GCC Countries

16.2.1.2. South Africa

16.2.1.3. Israel

16.2.1.4. Rest of MEA

16.2.2. By Therapy Type

16.2.3. By Route of Administration

16.2.4. By Patient Type

16.2.5. By Distribution Channel

16.3. Market Attractiveness Analysis

16.3.1. By Country

16.3.2. By Therapy Type

16.3.3. By Route of Administration

16.3.4. By Patient Type

16.3.5. By Distribution Channel

16.4. Key Takeaways

17. Key Countries Market Analysis

17.1. U.S.

17.1.1. Pricing Analysis

17.1.2. Market Share Analysis, 2023

17.1.2.1. By Therapy Type

17.1.2.2. By Route of Administration

17.1.2.3. By Patient Type

17.1.2.4. By Distribution Channel

17.2. Canada

17.2.1. Pricing Analysis

17.2.2. Market Share Analysis, 2023

17.2.2.1. By Therapy Type

17.2.2.2. By Route of Administration

17.2.2.3. By Patient Type

17.2.2.4. By Distribution Channel

17.3. Brazil

17.3.1. Pricing Analysis

17.3.2. Market Share Analysis, 2023

17.3.2.1. By Therapy Type

17.3.2.2. By Route of Administration

17.3.2.3. By Patient Type

17.3.2.4. By Distribution Channel

17.4. Mexico

17.4.1. Pricing Analysis

17.4.2. Market Share Analysis, 2023

17.4.2.1. By Therapy Type

17.4.2.2. By Route of Administration

17.4.2.3. By Patient Type

17.4.2.4. By Distribution Channel

17.5. Germany

17.5.1. Pricing Analysis

17.5.2. Market Share Analysis, 2023

17.5.2.1. By Therapy Type

17.5.2.2. By Route of Administration

17.5.2.3. By Patient Type

17.5.2.4. By Distribution Channel

17.6. U.K.

17.6.1. Pricing Analysis

17.6.2. Market Share Analysis, 2023

17.6.2.1. By Therapy Type

17.6.2.2. By Route of Administration

17.6.2.3. By Patient Type

17.6.2.4. By Distribution Channel

17.7. France

17.7.1. Pricing Analysis

17.7.2. Market Share Analysis, 2023

17.7.2.1. By Therapy Type

17.7.2.2. By Route of Administration

17.7.2.3. By Patient Type

17.7.2.4. By Distribution Channel

17.8. Spain

17.8.1. Pricing Analysis

17.8.2. Market Share Analysis, 2023

17.8.2.1. By Therapy Type

17.8.2.2. By Route of Administration

17.8.2.3. By Patient Type

17.8.2.4. By Distribution Channel

17.9. Italy

17.9.1. Pricing Analysis

17.9.2. Market Share Analysis, 2023

17.9.2.1. By Therapy Type

17.9.2.2. By Route of Administration

17.9.2.3. By Patient Type

17.9.2.4. By Distribution Channel

17.10. Poland

17.10.1. Pricing Analysis

17.10.2. Market Share Analysis, 2023

17.10.2.1. By Therapy Type

17.10.2.2. By Route of Administration

17.10.2.3. By Patient Type

17.10.2.4. By Distribution Channel

17.11. Russia

17.11.1. Pricing Analysis

17.11.2. Market Share Analysis, 2023

17.11.2.1. By Therapy Type

17.11.2.2. By Route of Administration

17.11.2.3. By Patient Type

17.11.2.4. By Distribution Channel

17.12. Czech Republic

17.12.1. Pricing Analysis

17.12.2. Market Share Analysis, 2023

17.12.2.1. By Therapy Type

17.12.2.2. By Route of Administration

17.12.2.3. By Patient Type

17.12.2.4. By Distribution Channel

17.13. Romania

17.13.1. Pricing Analysis

17.13.2. Market Share Analysis, 2023

17.13.2.1. By Therapy Type

17.13.2.2. By Route of Administration

17.13.2.3. By Patient Type

17.13.2.4. By Distribution Channel

17.14. India

17.14.1. Pricing Analysis

17.14.2. Market Share Analysis, 2023

17.14.2.1. By Therapy Type

17.14.2.2. By Route of Administration

17.14.2.3. By Patient Type

17.14.2.4. By Distribution Channel

17.15. Bangladesh

17.15.1. Pricing Analysis

17.15.2. Market Share Analysis, 2023

17.15.2.1. By Therapy Type

17.15.2.2. By Route of Administration

17.15.2.3. By Patient Type

17.15.2.4. By Distribution Channel

17.16. Australia

17.16.1. Pricing Analysis

17.16.2. Market Share Analysis, 2023

17.16.2.1. By Therapy Type

17.16.2.2. By Route of Administration

17.16.2.3. By Patient Type

17.16.2.4. By Distribution Channel

17.17. New Zealand

17.17.1. Pricing Analysis

17.17.2. Market Share Analysis, 2023

17.17.2.1. By Therapy Type

17.17.2.2. By Route of Administration

17.17.2.3. By Patient Type

17.17.2.4. By Distribution Channel

17.18. China

17.18.1. Pricing Analysis

17.18.2. Market Share Analysis, 2023

17.18.2.1. By Therapy Type

17.18.2.2. By Route of Administration

17.18.2.3. By Patient Type

17.18.2.4. By Distribution Channel

17.19. Japan

17.19.1. Pricing Analysis

17.19.2. Market Share Analysis, 2023

17.19.2.1. By Therapy Type

17.19.2.2. By Route of Administration

17.19.2.3. By Patient Type

17.19.2.4. By Distribution Channel

17.20. South Korea

17.20.1. Pricing Analysis

17.20.2. Market Share Analysis, 2023

17.20.2.1. By Therapy Type

17.20.2.2. By Route of Administration

17.20.2.3. By Patient Type

17.20.2.4. By Distribution Channel

17.21. GCC Countries

17.21.1. Pricing Analysis

17.21.2. Market Share Analysis, 2023

17.21.2.1. By Therapy Type

17.21.2.2. By Route of Administration

17.21.2.3. By Patient Type

17.21.2.4. By Distribution Channel

17.22. South Africa

17.22.1. Pricing Analysis

17.22.2. Market Share Analysis, 2023

17.22.2.1. By Therapy Type

17.22.2.2. By Route of Administration

17.22.2.3. By Patient Type

17.22.2.4. By Distribution Channel

17.23. Israel

17.23.1. Pricing Analysis

17.23.2. Market Share Analysis, 2023

17.23.2.1. By Therapy Type

17.23.2.2. By Route of Administration

17.23.2.3. By Patient Type

17.23.2.4. By Distribution Channel

18. Market Structure Analysis

18.1. Competition Dashboard

18.2. Competition Benchmarking

18.3. Market Share Analysis of Top Players

18.3.1. By Regional

18.3.2. By Therapy Type

18.3.3. By Route of Administration

18.3.4. By Patient Type

18.3.5. By Distribution Channel

19. Competition Analysis

19.1. Competition Deep Dive

19.1.1. Aquatic Remedies Pvt. Ltd.

19.1.1.1. Overview

19.1.1.2. Product Portfolio

19.1.1.3. Profitability by Market Segments

19.1.1.4. Sales Footprint

19.1.1.5. Strategy Overview

19.1.1.5.1. Marketing Strategy

19.1.2. Teva Pharmaceuticals USA, Inc.

19.1.2.1. Overview

19.1.2.2. Product Portfolio

19.1.2.3. Profitability by Market Segments

19.1.2.4. Sales Footprint

19.1.2.5. Strategy Overview

19.1.2.5.1. Marketing Strategy

19.1.3. Anglo French Drugs & Industries Limited

19.1.3.1. Overview

19.1.3.2. Product Portfolio

19.1.3.3. Profitability by Market Segments

19.1.3.4. Sales Footprint

19.1.3.5. Strategy Overview

19.1.3.5.1. Marketing Strategy

19.1.4. Biophar Lifesciences Pvt. Ltd.

19.1.4.1. Overview

19.1.4.2. Product Portfolio

19.1.4.3. Profitability by Market Segments

19.1.4.4. Sales Footprint

19.1.4.5. Strategy Overview

19.1.4.5.1. Marketing Strategy

19.1.5. Jasco Labs (P) Ltd.

19.1.5.1. Overview

19.1.5.2. Product Portfolio

19.1.5.3. Profitability by Market Segments

19.1.5.4. Sales Footprint

19.1.5.5. Strategy Overview

19.1.5.5.1. Marketing Strategy

19.1.6. BSA Pharma Inc.

19.1.6.1. Overview

19.1.6.2. Product Portfolio

19.1.6.3. Profitability by Market Segments

19.1.6.4. Sales Footprint

19.1.6.5. Strategy Overview

19.1.6.5.1. Marketing Strategy

19.1.7. Pfizer Inc.

19.1.7.1. Overview

19.1.7.2. Product Portfolio

19.1.7.3. Profitability by Market Segments

19.1.7.4. Sales Footprint

19.1.7.5. Strategy Overview

19.1.7.5.1. Marketing Strategy

19.1.8. Novartis AG

19.1.8.1. Overview

19.1.8.2. Product Portfolio

19.1.8.3. Profitability by Market Segments

19.1.8.4. Sales Footprint

19.1.8.5. Strategy Overview

19.1.8.5.1. Marketing Strategy

19.1.9. Sanofi S.A

19.1.9.1. Overview

19.1.9.2. Product Portfolio

19.1.9.3. Profitability by Market Segments

19.1.9.4. Sales Footprint

19.1.9.5. Strategy Overview

19.1.9.5.1. Marketing Strategy

19.1.10. AMAG Pharmaceuticals

19.1.10.1. Overview

19.1.10.2. Product Portfolio

19.1.10.3. Profitability by Market Segments

19.1.10.4. Sales Footprint

19.1.10.5. Strategy Overview

19.1.10.5.1. Marketing Strategy

19.1.11. Mylan

19.1.11.1. Overview

19.1.11.2. Product Portfolio

19.1.11.3. Profitability by Market Segments

19.1.11.4. Sales Footprint

19.1.11.5. Strategy Overview

19.1.11.5.1. Marketing Strategy

20. Assumptions & Acronyms Used

21. Research Methodology

Preterm Birth Prevention and Management Market

Preterm Birth Prevention and Management Market Forecast by Progesterone and Corticosteroid Therapy 2024 to 2034